Tackling COPD: A multicomponent disease driven by inflammation

MedGenMed Medscape General Medicine

Volumn 8, Issue 3, 2006, Pages

  Kardos, Peter ^a   Keenan, Joseph ^b  

^a Zentrum Maingau Krankenhaus   (Germany)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CICLESONIDE; CORTICOSTEROID; FENOTEROL PLUS IPRATROPIUM BROMIDE; FLUNISOLIDE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LONG ACTING DRUG; MOMETASONE FUROATE; MUCOLYTIC AGENT; OXYGEN; PHOSPHODIESTERASE IV INHIBITOR; SALMETEROL; SHORT ACTING DRUG; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DISEASE EXACERBATION; DRUG MECHANISM; DRUG POTENTIATION; EARLY INTERVENTION; HOSPITALIZATION; HUMAN; INFLAMMATION; LUNG STRUCTURE; MEDICAL DECISION MAKING; MEDICAL RESEARCH; META ANALYSIS; MONOTHERAPY; PATHOGENESIS; RISK FACTOR; SURVIVAL RATE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; PNEUMONIA; REVIEW;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; DRUG THERAPY, COMBINATION; HUMANS; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, ADRENERGIC, BETA-2;

EID: 33749571121     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. American Thoracic Society and European Respiratory Society. COPD Guidelines. Standards for the diagnosis and treatment. 2004. Available at: http://www.ersnet.org/ers/viewer_copd/mainFrame/default.aspx. Last accessed August 10, 2006.
2. European Respiratory Society and European Lung Foundation. European Lung White Book. The First Comprehensive Survey on Respiratory Health in Europe. 2003. European Respiratory Society and European Lung Foundation ISBN 1-904097-30-8.
3. van Schayck CP, Loozen JM, Wagena E, Akkermans RP, Wesseling GJ. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ. 2002;324:1370.
4. World Health Organization. The world health report 1997 - conquering suffering, enriching humanity. Available at: http://www.who.int/whr/1997/ en/. Last accessed August 10, 2006.
5. Soriano JB, Maier WC, Egger P, et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax. 2000;55:789-794. Abstract
6. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498-1504. Abstract
7. Price D, Tinkleman DG, Nordyke RJ, Isonaka S, Halbert RJ. Underdiagnosis of COPD and impact of a new diagnostic questionnaire. Eur Respir J. 2004;24(suppl 48):515s.
8. Price D, Tinkleman DG, Nordyke RJ, Isonaka S, Halbert RJ. Performance of COPD diagnostic questionnaires in patients with moderate and severe obstruction. Eur Respir J. 2004;24(suppl 48):473s.
9. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256-1276. Abstract
10. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease - updated 2005. Modena, Italy: Global Initiative for Chronic Obstructive Lung Disease; 2005.
11. Murray CJL, Lopez AD. The Global Burden of Disease: a Comprehensive Assessment of Mortality and Disability From Disease, Injuries and Risk Factors in 1990 and Projected to 2020. Cambridge, Mass: Harvard University Press; 1996.
12. British Thoracic Society. British Thoracic Society COPD guidelines summary. Thorax. 1997;52(suppl 5):1-32.
13. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care. 2003;48:1204-1213. Abstract
14. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55:114-120. Abstract
15. Garcia-Aymerich J, Farrero E, Felez MA, Izquierdo J, Marrades RM, Anto JM. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax. 2003;58:100-105. Abstract
16. Almagro P, Calbo E, Ochoa de Echaguen A, et al. Mortality after hospitalization for COPD. Chest. 2002;121:1441-1448. Abstract
17. Wouters EF. Economic analysis of the confronting COPD survey: an overview of results. Respir Med. 2003;97(suppl C):S3-14. Abstract
18. Gorecka D, Bednarek M, Nowinski A, et al. Diagnosis of airflow limitation combined with smoking cessation advice increases Stop-Smoking Rate. Chest. 2003;123:1916-1923. Abstract
19. Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:778-784. Abstract
20. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;115:957-965. Abstract
21. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002;19:209-216. Abstract
22. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J. 2000;320:1297-1303.
23. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999;340:1948-1953. Abstract
24. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343:1902-1909. Abstract
25. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353:1819-1823. Abstract
26. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74-81. Abstract
27. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361:449-456. Abstract
28. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22:912-919. Abstract
29. Hart L, Lim S, Adcock I, Barnes PJ, Chung KF. Effects of inhaled corticosteroid therapy on expression and DNA-binding activity of nuclear factor kappaB in asthma. Am J Respir Crit Care Med. 2000;161:224-231. Abstract
30. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004;23:698-702. Abstract
31. Worth H, Buhl R, Cegla U, et al. [Guidelines for the diagnosis and treatment chronic obstructive bronchitis and pulmonary emphysema issued by Deutsche Atemwegsliga and Deutsche Gesellschaft fur pneumologie]. Pneumologie. 2002;56:704-738. Abstract
32. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:347-360. Abstract
33. Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis. 1993;147:1151-1156. Abstract
34. Gosker HR, Wouters EF, van der Vusse GJ, Schols AM. Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives. Am J Clin Nutr. 2000;71:1033-1047. Abstract
35. Franssen FM, Broekhuizen R, Janssen PP, Wouters EF, Schols AM. Effects of whole-body exercise training on body composition and functional capacity in normal-weight patients with COPD. Chest. 2004;125:2021-2028. Abstract
36. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:1304-1309. Abstract
37. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med. 2001;164:S28-S38. Abstract
38. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574-580. Abstract
39. Agusti AG. COPD, a multicomponent disease: implications for management. Respir Med. 2005;99:670-682. Abstract
40. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645-2653. Abstract
41. Rutgers SR, Postma DS, ten Hacken NH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax. 2000;55:12-18. Abstract
42. Saetta M, Turato G, Facchini FM, et al. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med. 1997;156:1633-1639. Abstract
43. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107;1514-1519. Abstract
44. Rana JS, Mittleman MA, Sheikh J, et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care. 2004;27:2478-2484. Abstract
45. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev. 2001;14:336-363. Abstract
46. Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:822-826. Abstract
47. Turato G, Zuin R, Miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med. 2002;166:105-110. Abstract
48. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1618-1623. Abstract
49. Haskard DO. Accelerated atherosclerosis in inflammatory rheumatic diseases. Scand J Rheumatol. 2004;33:281-292. Abstract
50. Garrod R, Marshall J, Hagan GW, et al. CRP as a marker of impairment and disability in chronic obstructive pulmonary disease (COPD). Program and abstracts of the American Thoracic Society Annual Meeting; May 20-25, 2005; San Diego, California.
51. Bolton CE, Evans M, Ionescu AA, et al. Insulin resistance - a further systemic complication in COPD. Program and abstracts of the American Thoracic Society Annual Meeting; May 20-25, 2005; San Diego, California.
52. Hay DW. Chronic obstructive pulmonary disease: emerging therapies. Curr Opin Chem Biol. 2000;4:412-419. Abstract
53. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-946. Abstract
54. Sestini P, Renzoni E, Robinson S, Poole P, Ram FS. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;CD001495.
55. Beeh KM, Welte T, Buhl R. Anticholinergics in the treatment of chronic obstructive pulmonary disease. Respiration. 2002;69:372-379. Abstract
56. Gross NJ. Ipratropium bromide. N Engl J Med. 1988;319:486-494. Abstract
57. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125:2309-2321. Abstract
58. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217-224. Abstract
59. Maesen FP, Smeets JJ, Sledsens TJ, Wald FD, Cornelissen PJ. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J. 1995;8:1506-1513. Abstract
60. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143:317-326. Abstract
61. Culpitt SV, de Matos C, Russell RE, Donnelly LE, Rogers DF, Barnes PJ. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;165:1371-1376. Abstract
62. Petty TL. The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest. 1990;97:75-83. Abstract
63. Allegra L, Cordaro CI, Grassi C. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial. Respiration. 1996;63:174-180. Abstract
64. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365:1552-1560. Abstract
65. Gizycki MJ, Hattotuwa KL, Barnes N, Jeffery PK. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax. 2002;57:799-803. Abstract
66. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med. 2002;165:1592-1596. Abstract
67. Yildiz F, Kaur AC, Ilgazli A, et al. Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease. Respiration. 2000;67:71-76. Abstract
68. Balbi B, Majori M, Bertacco S, et al. Inhaled corticosteroids in stable COPD patients: Do they have effects on cells and molecular mediators of airway inflammation? Chest. 2000;117:1633-1637.
69. Confalonieri M, Mainardi E, Delia PR, et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax. 1998;53:583-585. Abstract
70. Verhoeven GT, Hegmans JP, Mulder PG, Bogaard JM, Hoogsteden HC, Prins JB. Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax. 2002;57:694-700. Abstract
71. Leigh R, Pizzichini MM, Morris M, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: predicting benefit from high dose inhaled corticosteroid treatment. Eur Respir J. 2006;27:964-971. Abstract
72. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:760-765. Abstract
73. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med. 2002;113:59-65. Abstract
74. [No authors listed]. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest. 1994;105:1411-1419. Abstract
75. Imhof E, Elsasser S, Karrer W, Grossenbacher M, Emmons R, Perruchoud AP. Comparison of bronchodilator effects of fenoterol/ipratropium bromide and salbutamol in patients with chronic obstructive lung disease. Respiration. 1993;60:84-88. Abstract
76. van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005;26:214-222. Abstract
77. Cazzola M, Centanni S, Santus P, et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med. 2004;98:1214-1221. Abstract
78. Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2004;CD003794.
79. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:1084-1091. Abstract
80. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax. 2005;60:992-997. Abstract
81. Soriano JB, Kiri VA, Pride NB, et al. Inhaled corticosteroids with/ without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Crit Care Med. 2003;2:67-74.
82. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J. 2002;20:819-825. Abstract
83. van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J. 2000;15:878-885. Abstract
84. Bourbeau J, Julien M, Maltais F, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med. 2003;163:585-591. Abstract
85. Barnes NC, Qui Y, Pavord I, et al. Salmeterol/fluticasone propionate (SFC): anti-inflammatory effects in COPD. Am J Respir Crit Care Med. 2006;173:736-743. Abstract
86. Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J. 2004;24:206-210. Abstract
87. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med. 1980;93:391-398. Abstract
88. Cranston JM, Crockett AJ, Moss JR, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;CD001744.
89. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1985;131:493-498. Abstract
90. Eaton T, Garrett JE, Young P, et al. Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study. Eur Respir J. 2002;20:306-312. Abstract
91. Lacasse Y, Lecours R, Pelletier C, Begin R, Maltais F. Randomised trial of ambulatory oxygen in oxygen-dependent COPD. Eur Respir J. 2005;25:1032-1038. Abstract
92. British Thoracic Society Standards of Care Subcommittee on Pulmonary Rehabilitation. Pulmonary rehabilitation. Thorax. 2001;56:827-834. Abstract
93. Schols AM, Soeters PB, Mostert R, Pluymers RJ, Wouters EF. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med. 1995;152:1268-1274. Abstract
94. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1791-1797. Abstract
95. Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;CD002733.
96. Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax. 2006;61:189-195. Abstract
97. Griffiths TL, Burr ML, Campbell IA, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet. 2000;355:362-368. Abstract
98. Gallefoss F, Bakke PS. Cost-benefit and cost-effectiveness analysis of self-management in patients with COPD - a 1-year follow-up randomized, controlled trial. Respir Med. 2002;96:424-431. Abstract
99. Cooper JD, Patterson GA, Sundaresan RS, et al. Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema. J Thorac Cardiovasc Surg. 1996;112:1319-1329. Abstract
100. Barnes PJ. Therapy of chronic obstructive pulmonary disease. Pharmacol Ther. 2003;97:87-94. Abstract